Beijing Centergate Technologies Units' 34 Drugs Secure Spot on China's Insurance Drug Catalog for 2024; Shares Up 4%

MT Newswires Live2024-12-12

Thirty four drugs of Beijing Centergate Technologies Holding's (SHE:000931) pharmaceutical subsidiaries were included in China's National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Catalog for 2024, according to a Shenzhen Stock Exchange filing on Wednesday.

The list included bisoprolol fumarate tablets, benidipine hydrochloride tablets, oxycodone hydrochloride tablets, and naloxone hydrochloride injection, among others.

Some of the drugs were already included in the 2023 catalog.

The catalog for the year will be implemented on Jan. 1, 2025, the filing said.

The residential and office building developer's shares jumped over 4% in recent trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment